Traders should monitor upcoming FDA feedback and initiation of the TNX-4800 field study in 2027 as next catalysts; while PK data is encouraging, absence of efficacy data limits near-term upside. Insider buying may suggest confidence, but no material financial updates were provided.
Price Chart
Executive Summary
Tonix Pharmaceuticals presented Phase 1 data for TNX-4800, a long-acting monoclonal antibody for seasonal prevention of Lyme disease, demonstrating favorable pharmacokinetics with serum concentrations detectable for up to 12 months and a half-life of 62–69 days. The company also highlighted preclinical work on TNX-801, a live attenuated horsepox-based vaccine candidate for smallpox and mpox, with plans for Phase 1 initiation in 2027 pending FDA clearance. No efficacy endpoints or clinical protection data were reported, and the announcement is primarily developmental in nature.
Key Facts
- TNX-4800 Phase 1 study showed serum concentrations remained quantifiable for >200 days at the lowest dose (0.5 mg/kg) and up to 350 days at higher doses (≥1.5 mg/kg)
- Mean half-life of TNX-4800 ranged from 62 to 69 days across dose groups
- TNX-4800 was generally safe and well-tolerated with no significant immunogenicity (anti-drug antibodies in <10% of subjects)
- No clinical efficacy data from human challenge or field studies were presented — only pharmacokinetic and safety data
- TNX-801 (horsepox vaccine) remains in pre-IND stage with Phase 1 expected in 2027 pending FDA clearance
- GMP investigational product for TNX-4800 expected in early 2027; field study planned for first half of 2027, CHIM study in 2028
Financial Impact
No immediate financial impact — data supports continued development but no commercial or revenue implications near-term
Risk Factors
- No efficacy data yet — protection against Lyme disease remains unproven in humans
- Development timelines are multi-year (field study in 2027, CHIM in 2028), increasing execution and funding risk
- Highly competitive landscape for Lyme prevention, including vaccines in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260859 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $5.73 | awaiting T+20 | — | $5.43 (−5.24%) |
Oct 15, 2026 12d ago | 8-K | $6.42 | awaiting T+20 | — | $5.43 (−15.42%) |
Oct 2, 2026 24d ago | 8-K | $8.07 | awaiting T+20 | — | $5.43 (+32.71%) |
Sep 22, 2026 5w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.43 (−48.73%) |
Sep 8, 2026 7w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.43 (−58.74%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.43 (−56.87%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.43 (−56.87%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.43 (−49.11%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.43 (−47.64%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.43 (−53.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers